Epoxyeicosatrienoic acids (EETs) decrease cardiac ischemia-reperfusion injury; however, the mechanism of their protective effect remains elusive. Here, we investigated the cardioprotective action of a novel EET analog, EET-B, in reperfusion and the role of hypoxia-inducible factor (HIF)-1α in such action of EET-B. Adult male rats were subjected to 30 min of left coronary artery occlusion followed by 2 h of reperfusion. Administration of 14,15-EET (2.5 mg/kg) or EET-B (2.5 mg/kg) 5 min before reperfusion reduced infarct size expressed as a percentage of the area at risk from 64.3 ± 1.3% in control to 42.6 ± 1.9% and 46.0 ± 1.6%, respectively, and their coadministration did not provide any stronger effect. The 14,15-EET antagonist 14,15-epoxyeicosa-5( Z)-enoic acid (2.5 mg/kg) inhibited the infarct size-limiting effect of EET-B (62.5 ± 1.1%). Similarly, the HIF-1α inhibitors 2-methoxyestradiol (2.5 mg/kg) and acriflavine (2 mg/kg) completely abolished the cardioprotective effect of EET-B. In a separate set of experiments, the immunoreactivity of HIF-1α and its degrading enzyme prolyl hydroxylase domain protein 3 (PHD3) were analyzed in the ischemic areas and nonischemic septa. At the end of ischemia, the HIF-1α immunogenic signal markedly increased in the ischemic area compared with the septum (10.31 ± 0.78% vs. 0.34 ± 0.08%). After 20 min and 2 h of reperfusion, HIF-1α immunoreactivity decreased to 2.40 ± 0.48% and 1.85 ± 0.43%, respectively, in the controls. EET-B blunted the decrease of HIF-1α immunoreactivity (7.80 ± 0.69% and 6.44 ± 1.37%, respectively) and significantly reduced PHD3 immunogenic signal in ischemic tissue after reperfusion. In conclusion, EET-B provides an infarct size-limiting effect at reperfusion that is mediated by HIF-1α and downregulation of its degrading enzyme PHD3. NEW & NOTEWORTHY The present study shows that EET-B is an effective agonistic 14,15-epoxyeicosatrienoic acid analog, and its administration before reperfusion markedly reduced myocardial infarction in rats. Most importantly, we demonstrate that increased hypoxia-inducible factor-1α levels play a role in cardioprotection mediated by EET-B in reperfusion likely by mechanisms including downregulation of the hypoxia-inducible factor -1α-degrading enzyme prolyl hydroxylase domain protein 3.

Center for Experimental Medicine Institute for Clinical and Experimental Medicine Physiology Prague Czech Republic

Department of Biochemistry University of Texas Southwestern Medical Center Dallas Texas

Department of Developmental Cardiology Institute of Physiology of the Czech Academy of Sciences Prague Czech Republic

Department of Pharmacology and Toxicology Medical College of Wisconsin Milwaukee Wisconsin

Institute of Anatomy 1st Faculty of Medicine Charles University Prague Czech Republic

Zobrazit více v PubMed

Alánová P, Husková Z, Kopkan L, Sporková A, Jíchová Š, Neckář J, Imig JD, Klevstig M, Kolář F, Rami Reddy N, Falck JR, Sadowski J, Nishiyama A, Kramer HJ, Melenovský V, Červenková L, Kujal P, Vernerová Z, Červenka L. Orally active epoxyeicosatrienoic acid analog does not exhibit antihypertensive and reno- or cardioprotective actions in two-kidney, one-clip Goldblatt hypertensive rats. Vascul Pharmacol 73: 45–56, 2015. doi:10.1016/j.vph.2015.08.013. PubMed DOI

Alexander-Shani R, Mreisat A, Smeir E, Gerstenblith G, Stern MD, Horowitz M. Long-term HIF-1α transcriptional activation is essential for heat-acclimation-mediated cross tolerance: mitochondrial target genes. Am J Physiol Regul Integr Comp Physiol 312: R753–R762, 2017. doi:10.1152/ajpregu.00461.2016. PubMed DOI PMC

Batchu SN, Lee SB, Samokhvalov V, Chaudhary KR, El-Sikhry H, Weldon SM, Seubert JM. Novel soluble epoxide hydrolase inhibitor protects mitochondrial function following stress. Can J Physiol Pharmacol 90: 811–823, 2012. doi:10.1139/y2012-082. PubMed DOI

Batchu SN, Lee SB, Qadhi RS, Chaudhary KR, El-Sikhry H, Kodela R, Falck JR, Seubert JM. Cardioprotective effect of a dual acting epoxyeicosatrienoic acid analogue towards ischaemia reperfusion injury. Br J Pharmacol 162: 897–907, 2011. doi:10.1111/j.1476-5381.2010.01093.x. PubMed DOI PMC

Belibi F, Zafar I, Ravichandran K, Segvic AB, Jani A, Ljubanovic DG, Edelstein CL. Hypoxia-inducible factor-1α (HIF-1α) and autophagy in polycystic kidney disease (PKD). Am J Physiol Renal Physiol 300: F1235–F1243, 2011. doi:10.1152/ajprenal.00348.2010. PubMed DOI PMC

Berra E, Benizri E, Ginouvès A, Volmat V, Roux D, Pouysségur J. HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1α in normoxia. EMBO J 22: 4082–4090, 2003. doi:10.1093/emboj/cdg392. PubMed DOI PMC

Cao J, Tsenovoy PL, Thompson EA, Falck JR, Touchon R, Sodhi K, Rezzani R, Shapiro JI, Abraham NG. Agonists of epoxyeicosatrienoic acids reduce infarct size and ameliorate cardiac dysfunction via activation of HO-1 and Wnt1 canonical pathway. Prostaglandins Other Lipid Mediat 116-117: 76–86, 2015. doi:10.1016/j.prostaglandins.2015.01.002. PubMed DOI PMC

Cai Z, Zhong H, Bosch-Marce M, Fox-Talbot K, Wang L, Wei C, Trush MA, Semenza GL. Complete loss of ischaemic preconditioning-induced cardioprotection in mice with partial deficiency of HIF-1 alpha. Cardiovasc Res 77: 463–470, 2008. doi:10.1093/cvr/cvm035. PubMed DOI

Chaudhary KR, Abukhashim M, Hwang SH, Hammock BD, Seubert JM. Inhibition of soluble epoxide hydrolase by trans-4- [4-(3-adamantan-1-yl-ureido)-cyclohexyloxy]-benzoic acid is protective against ischemia-reperfusion injury. J Cardiovasc Pharmacol 55: 67–73, 2010. doi:10.1097/FJC.0b013e3181c37d69. PubMed DOI PMC

Dai Y, Xu M, Wang Y, Pasha Z, Li T, Ashraf M. HIF-1α induced-VEGF overexpression in bone marrow stem cells protects cardiomyocytes against ischemia. J Mol Cell Cardiol 42: 1036–1044, 2007. doi:10.1016/j.yjmcc.2007.04.001. PubMed DOI PMC

Eckle T, Köhler D, Lehmann R, El Kasmi K, Eltzschig HK. Hypoxia-inducible factor-1 is central to cardioprotection: a new paradigm for ischemic preconditioning. Circulation 118: 166–175, 2008. doi:10.1161/CIRCULATIONAHA.107.758516. PubMed DOI

Gross GJ, Falck JR, Gross ER, Isbell M, Moore J, Nithipatikom K. Cytochrome P450 and arachidonic acid metabolites: role in myocardial ischemia/reperfusion injury revisited. Cardiovasc Res 68: 18–25, 2005. doi:10.1016/j.cardiores.2005.06.007. PubMed DOI

Gross GJ, Hsu A, Falck JR, Nithipatikom K. Mechanisms by which epoxyeicosatrienoic acids (EETs) elicit cardioprotection in rat hearts. J Mol Cell Cardiol 42: 687–691, 2007. doi:10.1016/j.yjmcc.2006.11.020. PubMed DOI PMC

Gross GJ, Hsu A, Pfeiffer AW, Nithipatikom K. Roles of endothelial nitric oxide synthase (eNOS) and mitochondrial permeability transition pore (MPTP) in epoxyeicosatrienoic acid (EET)-induced cardioprotection against infarction in intact rat hearts. J Mol Cell Cardiol 59: 20–29, 2013. doi:10.1016/j.yjmcc.2013.02.003. PubMed DOI PMC

Huang T, Huang W, Zhang Z, Yu L, Xie C, Zhu D, Peng Z, Chen J. Hypoxia-inducible factor-1α upregulation in microglia following hypoxia protects against ischemia-induced cerebral infarction. Neuroreport 25: 1122–1128, 2014. doi:10.1097/WNR.0000000000000236. PubMed DOI

Hye Khan MA, Neckář J, Manthati V, Errabelli R, Pavlov TS, Staruschenko A, Falck JR, Imig JD. Orally active epoxyeicosatrienoic acid analog attenuates kidney injury in hypertensive Dahl salt-sensitive rat. Hypertension 62: 905–913, 2013. doi:10.1161/HYPERTENSIONAHA.113.01949. PubMed DOI PMC

Hye Khan MA, Pavlov TS, Christain SV, Neckář J, Staruschenko A, Gauthier KM, Capdevila JH, Falck JR, Campbell WB, Imig JD. Epoxyeicosatrienoic acid analogue lowers blood pressure through vasodilation and sodium channel inhibition. Clin Sci (Lond) 127: 463–474, 2014. doi:10.1042/CS20130479. PubMed DOI PMC

Imig JD. Epoxides and soluble epoxide hydrolase in cardiovascular physiology. Physiol Rev 92: 101–130, 2012. doi:10.1152/physrev.00021.2011. PubMed DOI PMC

Imig JD, Elmarakby A, Nithipatikom K, Wei S, Capdevila JH, Tuniki VR, Sangras B, Anjaiah S, Manthati VL, Sudarshan Reddy D, Falck JR. Development of epoxyeicosatrienoic acid analogs with in vivo anti-hypertensive actions. Front Physiol 1: 157, 2010. doi:10.3389/fphys.2010.00157. PubMed DOI PMC

Khan MA, Liu J, Kumar G, Skapek SX, Falck JR, Imig JD. Novel orally active epoxyeicosatrienoic acid (EET) analogs attenuate cisplatin nephrotoxicity. FASEB J 27: 2946–2956, 2013. doi:10.1096/fj.12-218040. PubMed DOI PMC

Lee K, Zhang H, Qian DZ, Rey S, Liu JO, Semenza GL. Acriflavine inhibits HIF-1 dimerization, tumor growth, and vascularization. Proc Natl Acad Sci USA 106: 17910–17915, 2009. doi:10.1073/pnas.0909353106. PubMed DOI PMC

Luo C, Ouyang MW, Fang YY, Li SJ, Zhou Q, Fan J, Qin ZS, Tao T. Dexmedetomidine protects mouse brain from ischemia-reperfusion injury via inhibiting neuronal autophagy through up-regulating HIF-1α. Front Cell Neurosci 11: 197, 2017. doi:10.3389/fncel.2017.00197. PubMed DOI PMC

Mabjeesh NJ, Escuin D, LaVallee TM, Pribluda VS, Swartz GM, Johnson MS, Willard MT, Zhong H, Simons JW, Giannakakou P. 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell 3: 363–375, 2003. doi:10.1016/S1535-6108(03)00077-1. PubMed DOI

Mao X, Wang T, Liu Y, Irwin MG, Ou JS, Liao XL, Gao X, Xu Y, Ng KF, Vanhoutte PM, Xia Z. N-acetylcysteine and allopurinol confer synergy in attenuating myocardial ischemia injury via restoring HIF-1α/HO-1 signaling in diabetic rats. PLoS One 8: e68949, 2013. doi:10.1371/journal.pone.0068949. PubMed DOI PMC

Metzen E, Berchner-Pfannschmidt U, Stengel P, Marxsen JH, Stolze I, Klinger M, Huang WQ, Wotzlaw C, Hellwig-Bürgel T, Jelkmann W, Acker H, Fandrey J. Intracellular localisation of human HIF-1 alpha hydroxylases: implications for oxygen sensing. J Cell Sci 116: 1319–1326, 2003. doi:10.1242/jcs.00318. PubMed DOI

Motoki A, Merkel MJ, Packwood WH, Cao Z, Liu L, Iliff J, Alkayed NJ, Van Winkle DM. Soluble epoxide hydrolase inhibition and gene deletion are protective against myocardial ischemia-reperfusion injury in vivo. Am J Physiol Heart Circ Physiol 295: H2128–H2134, 2008. doi:10.1152/ajpheart.00428.2008. PubMed DOI PMC

Nakayama K, Gazdoiu S, Abraham R, Pan ZQ, Ronai Z. Hypoxia-induced assembly of prolyl hydroxylase PHD3 into complexes: implications for its activity and susceptibility for degradation by the E3 ligase Siah2. Biochem J 401: 217–226, 2007. doi:10.1042/BJ20061135. PubMed DOI PMC

Natarajan R, Salloum FN, Fisher BJ, Ownby ED, Kukreja RC, Fowler AA III. Activation of hypoxia-inducible factor-1 via prolyl-4 hydoxylase-2 gene silencing attenuates acute inflammatory responses in postischemic myocardium. Am J Physiol Heart Circ Physiol 293: H1571–H1580, 2007. doi:10.1152/ajpheart.00291.2007. PubMed DOI

Neckář J, Kopkan L, Husková Z, Kolář F, Papoušek F, Kramer HJ, Hwang SH, Hammock BD, Imig JD, Malý J, Netuka I, Ošťádal B, Červenka L. Inhibition of soluble epoxide hydrolase by cis-4-[4-(3-adamantan-1-ylureido)cyclohexyl-oxy]benzoic acid exhibits antihypertensive and cardioprotective actions in transgenic rats with angiotensin II-dependent hypertension. Clin Sci (Lond) 122: 513–525, 2012. doi:10.1042/CS20110622. PubMed DOI PMC

Nithipatikom K, Moore JM, Isbell MA, Falck JR, Gross GJ. Epoxyeicosatrienoic acids in cardioprotection: ischemic versus reperfusion injury. Am J Physiol Heart Circ Physiol 291: H537–H542, 2006. doi:10.1152/ajpheart.00071.2006. PubMed DOI

Ockaili R, Natarajan R, Salloum F, Fisher BJ, Jones D, Fowler AA III, Kukreja RC. HIF-1 activation attenuates postischemic myocardial injury: role for heme oxygenase-1 in modulating microvascular chemokine generation. Am J Physiol Heart Circ Physiol 289: H542–H548, 2005. doi:10.1152/ajpheart.00089.2005. PubMed DOI

Oni-Orisan A, Alsaleh N, Lee CR, Seubert JM. Epoxyeicosatrienoic acids and cardioprotection: the road to translation. J Mol Cell Cardiol 74: 199–208, 2014. doi:10.1016/j.yjmcc.2014.05.016. PubMed DOI PMC

Ong SG, Hausenloy DJ. Hypoxia-inducible factor as a therapeutic target for cardioprotection. Pharmacol Ther 136: 69–81, 2012. doi:10.1016/j.pharmthera.2012.07.005. PubMed DOI

Prabhakar NR, Semenza GL. Adaptive and maladaptive cardiorespiratory responses to continuous and intermittent hypoxia mediated by hypoxia-inducible factors 1 and 2. Physiol Rev 92: 967–1003, 2012. doi:10.1152/physrev.00030.2011. PubMed DOI PMC

Rand AA, Barnych B, Morisseau C, Cajka T, Lee KSS, Panigrahy D, Hammock BD. Cyclooxygenase-derived proangiogenic metabolites of epoxyeicosatrienoic acids. Proc Natl Acad Sci USA 114: 4370–4375, 2017. doi:10.1073/pnas.1616893114. PubMed DOI PMC

Sarkar K, Cai Z, Gupta R, Parajuli N, Fox-Talbot K, Darshan MS, Gonzalez FJ, Semenza GL. Hypoxia-inducible factor 1 transcriptional activity in endothelial cells is required for acute phase cardioprotection induced by ischemic preconditioning. Proc Natl Acad Sci USA 109: 10504–10509, 2012. doi:10.1073/pnas.1208314109. PubMed DOI PMC

Semenza GL. Hypoxia-inducible factors in physiology and medicine. Cell 148: 399–408, 2012. doi:10.1016/j.cell.2012.01.021. PubMed DOI PMC

Semenza GL. Hypoxia-inducible factor 1: regulator of mitochondrial metabolism and mediator of ischemic preconditioning. Biochim Biophys Acta 1813: 1263–1268, 2011. doi:10.1016/j.bbamcr.2010.08.006. PubMed DOI PMC

Seubert JM, Zeldin DC, Nithipatikom K, Gross GJ. Role of epoxyeicosatrienoic acids in protecting the myocardium following ischemia/reperfusion injury. Prostaglandins Other Lipid Mediat 82: 50–59, 2007. doi:10.1016/j.prostaglandins.2006.05.017. PubMed DOI PMC

Seubert J, Yang B, Bradbury JA, Graves J, Degraff LM, Gabel S, Gooch R, Foley J, Newman J, Mao L, Rockman HA, Hammock BD, Murphy E, Zeldin DC. Enhanced postischemic functional recovery in CYP2J2 transgenic hearts involves mitochondrial ATP-sensitive K+ channels and p42/p44 MAPK pathway. Circ Res 95: 506–514, 2004. doi:10.1161/01.RES.0000139436.89654.c8. PubMed DOI

Si J, Wang N, Wang H, Xie J, Yang J, Yi H, Shi Z, Ma J, Wang W, Yang L, Yu S, Li J. HIF-1α signaling activation by post-ischemia treatment with astragaloside IV attenuates myocardial ischemia-reperfusion injury. PLoS One 9: e107832, 2014. doi:10.1371/journal.pone.0107832. PubMed DOI PMC

Suzuki S, Oguro A, Osada-Oka M, Funae Y, Imaoka S. Epoxyeicosatrienoic acids and/or their metabolites promote hypoxic response of cells. J Pharmacol Sci 108: 79–88, 2008. doi:10.1254/jphs.08122FP. PubMed DOI

Umschweif G, Alexandrovich AG, Trembovler V, Horowitz M, Shohami E. Hypoxia-inducible factor 1 is essential for spontaneous recovery from traumatic brain injury and is a key mediator of heat acclimation induced neuroprotection. J Cereb Blood Flow Metab 33: 524–531, 2013. doi:10.1038/jcbfm.2012.193. PubMed DOI PMC

Vogler M, Zieseniss A, Hesse AR, Levent E, Tiburcy M, Heinze E, Burzlaff N, Schley G, Eckardt KU, Willam C, Katschinski DM. Pre- and post-conditional inhibition of prolyl-4-hydroxylase domain enzymes protects the heart from an ischemic insult. Pflugers Arch 467: 2141–2149, 2015. doi:10.1007/s00424-014-1667-z. PubMed DOI

Wang GL, Semenza GL. Purification and characterisation of hypoxia-inducible factor 1. J Biol Chem 270: 1230–1237, 1995. PubMed

Wu J, Yang L, Xie P, Yu J, Yu T, Wang H, Maimaitili Y, Wang J, Ma H, Yang Y, Zheng H. Cobalt chloride upregulates impaired HIF-1α expression to restore sevoflurane post-conditioning-dependent myocardial protection in diabetic rats. Front Physiol 8: 395, 2017. doi:10.3389/fphys.2017.00395. PubMed DOI PMC

Xie P, Yang L, Talaiti A, Wu JJ, Yu J, Yu T, Wang HY, Huang B, Wu Q, Maimaitili Y, Wang J, Ma HP, Yang YN, Zheng H. Deferoxamine-activated hypoxia-inducible factor-1 restores cardioprotective effects of sevoflurane postconditioning in diabetic rats. Acta Physiol (Oxf) 221: 98–114, 2017. doi:10.1111/apha.12874. PubMed DOI

Xu DY, Davis BB, Wang ZH, Zhao SP, Wasti B, Liu ZL, Li N, Morisseau C, Chiamvimonvat N, Hammock BD. A potent soluble epoxide hydrolase inhibitor, t-AUCB, acts through PPARγ to modulate the function of endothelial progenitor cells from patients with acute myocardial infarction. Int J Cardiol 167: 1298–1304, 2013. doi:10.1016/j.ijcard.2012.03.167. PubMed DOI PMC

Yang L, Xie P, Wu J, Yu J, Yu T, Wang H, Wang J, Xia Z, Zheng H. Sevoflurane postconditioning improves myocardial mitochondrial respiratory function and reduces myocardial ischemia-reperfusion injury by up-regulating HIF-1. Am J Transl Res 8: 4415–4424, 2016. PubMed PMC

Yu GG, Zeng XJ, Wang HX, Lu LQ, Zheng SP, Ma LQ, Chang J, Wang J, Zhang DM, Du FH, Zhang LK. Cytochrome P450 2J3/epoxyeicosatrienoic acids mediate the cardioprotection induced by ischaemic post-conditioning, but not preconditioning, in the rat. Clin Exp Pharmacol Physiol 38: 63–70, 2011. doi:10.1111/j.1440-1681.2010.05464.x. PubMed DOI

Zhao HX, Wang XL, Wang YH, Wu Y, Li XY, Lv XP, Zhao ZQ, Zhao RR, Liu HR. Attenuation of myocardial injury by postconditioning: role of hypoxia inducible factor-1alpha. Basic Res Cardiol 105: 109–118, 2010. doi:10.1007/s00395-009-0044-0. PubMed DOI

Zhou D, Matchett GA, Jadhav V, Dach N, Zhang JH. The effect of 2-methoxyestradiol, a HIF-1 alpha inhibitor, in global cerebral ischemia in rats. Neurol Res 30: 268–271, 2008. doi:10.1179/016164107X229920. PubMed DOI PMC

Zhu T, Zhan L, Liang D, Hu J, Lu Z, Zhu X, Sun W, Liu L, Xu E. Hypoxia-inducible factor 1α mediates neuroprotection of hypoxic postconditioning against global cerebral ischemia. J Neuropathol Exp Neurol 73: 975–986, 2014. doi:10.1097/NEN.0000000000000118. PubMed DOI

Zieseniss A, Hesse AR, Jatho A, Krull S, Hölscher M, Vogel S, Katschinski DM. Cardiomyocyte-specific transgenic expression of prolyl-4-hydroxylase domain 3 impairs the myocardial response to ischemia. Cell Physiol Biochem 36: 843–851, 2015. doi:10.1159/000430260. PubMed DOI

Unveiling the proteome of the fasting heart: Insights into HIF-1 pathway regulation

Sixty Years of Heart Research in the Institute of Physiology of the Czech Academy of Sciences

Epitranscriptomic regulation in fasting hearts: implications for cardiac health

Epoxylipids and soluble epoxide hydrolase in heart diseases

Epoxyeicosanoids in hypertension

Epoxyeicosatrienoic acid analog EET-B attenuates post-myocardial infarction remodeling in spontaneously hypertensive rats

Epoxyeicosatrienoic Acid-Based Therapy Attenuates the Progression of Postischemic Heart Failure in Normotensive Sprague-Dawley but Not in Hypertensive Ren-2 Transgenic Rats